Kimme Hyrich

Overview

I am a Professor of Epidemiology in the Arthritis Research UK Centre for Epidemiology, part of the Centre for Musculoskeletal Research and a Consultant Rheumatologist in the Kellgren Centre for Rheumatology at Central Manchester University Hospitals NHS Foundation Trust. 

I am also the Programme Director for the MRes in Medical Sciences (for intercalatintg medical students and NIHR Academic Clinical Fellows) and Epidemiology Module Lead for the MSc in Clinical Rheumatology.

I am a clinical epidemiologist and my main research interests are understanding the short and longterm outcomes in adult and childhood inflammatory arthritis, including a greater understanding of the role treatments play in these outcomes.

Biography

I completed my Bachelors of Science and medical degree at the University of Manitoba in Canada. This was followed by training in internal medicine in Winnipeg, Canada and a fellowship in rheumatology at the University of Toronto. I subsequently worked as an Arthritis Society of Canada/CIHR Research Fellow at the Arthritis Research UK (formerly arc) Epidemiology Unit in Manchester, being awarded my PhD in 2005. I joined this unit as a Senior Lecturer in 2006 and  I am now  Professor of Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary, Manchester, UK.

My main research interests centre on outcomes in inflammatory arthritis, with a particular focus on pharmacoepidemiology. I am a principal investigator for the British Society for Rheumatology Biologics Register (BSRBR), which is prospectively collecting information on all patients receiving biologic therapy for a rheumatic disease throughout the United Kingdom. Work from this project has assessed the real-world efficacy of anti-TNF agents for rheumatoid arthritis as well as predictors of response and the risk of adverse events, including infection and myocardial infarction. My research in paediatrics includes the Childhood Arthritis Prospective Study (CAPS), an inception cohort which is studying both short and long-term outcomes in children diagnosed in the UK with juvenile idiopathic arthritis and 2 biologic registers in children: the Arthritis Research UK funded Safety and Efficacy of Biologics in Children (Extended Biologics Study) and the BSPAR Etanercept Register, which is focusing on the short and long-term safety of the use of biologic drugs in children with arthritis.

I supervise a number of PhD and Masters students working on these and related projects.